Antihypertensive treatment: prevention of cardiovascular disease and prevention of events. Satellite symposiumHANSSON, Lennart.Journal of cardiovascular pharmacology. 1992, Vol 19, issn 0160-2446, 108 p., SUP3Conference Proceedings

Antiatherosclerotic actions of isradipineSINZINGER, H; FITSCHA, P.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S29-S31, issn 0160-2446, SUP3Conference Paper

Vascular mechanisms in hypertensive cerebrovascular diseaseJOHANSSON, B. B.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S11-S15, issn 0160-2446, SUP3Conference Paper

Isradipine in the treatment of hypertensive crisis in ambulatory patientsSARAGOCA, M. A; PORTELA, J. E; PLAVNIK, F et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S76-S78, issn 0160-2446, SUP3Conference Paper

Isradipine in the treatment of mild-to-moderate hypertension in PortugalPEREIRA-MIGUEL, J. M; CORREA-NUNES, A; ROCHA-GONCALVES, F et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S49-S52, issn 0160-2446, SUP3Conference Paper

Cardiovascular diseases, blood rheology, and dihydropyridine calcium antagonistsSLONIM, A; CRISTAL, N.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S96-S98, issn 0160-2446, SUP3Conference Paper

Effects of isradipine on hypertension and renal hemodynamicsSIAMOPOULOS, K. C; ELISAF, M; DARDAMANIS, M et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S87-S89, issn 0160-2446, SUP3Conference Paper

Hemodynamic effects of isradipine and nifedipine in chronic sustained hypertensionGROSS, P; KOPPENHAGEN, K; WUDEL, E et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S84-S86, issn 0160-2446, SUP3Conference Paper

Long-term (2-year) isradipine data in the treatment of mild-to-moderate hypertensionD'HONT, G; MEURANT, J. P; CLEMENT, D. L et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S46-S48, issn 0160-2446, SUP3Conference Paper

Platelet activation by low-density lipoprotein and serotonin: effects of calcium antagonistsFETKOVSKA, N.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S25-S28, issn 0160-2446, SUP3Conference Paper

Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipineTÖRÖK, E; BORBAS, S; LENGYEL, M et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S79-S83, issn 0160-2446, SUP3Conference Paper

Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patientsBATLOUNI, M; ARMAGANIJAN, D; GHORAYEB, N et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S53-S57, issn 0160-2446, SUP3Conference Paper

Effects of long-term administration of isradipine on renal hemodynamics and sodium metabolismFRANCISCHETTI, E. A; BARROSO A. DE SILVA, I; FAGUNDES, V. G. A et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S90-S92, issn 0160-2446, SUP3Conference Paper

MIDAS: hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosisBORHANI, N. O; MILLER, S. T; BRUGGER, S. B et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S16-S20, issn 0160-2446, SUP3Conference Paper

Pharmacological modulation of stress-induced cardiovascular hyperreactivity in essential hypertensionSCHULTE, W; RÜDDEL, H; SCHMIEDER, R et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S70-S73, issn 0160-2446, SUP3Conference Paper

Does isradipine exert a special early-morning blood pressure-lowering effect?VISKOPER, J. R; LASZT, A; FARAGGI, D et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S74-S75, issn 0160-2446, SUP3Conference Paper

Effects of isradipine on responses to standardized physical stress tests in hypertension of pregnancyLUNELL, N.-O; GRUNEWALD, C; NISELL, H et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S99-S101, issn 0160-2446, SUP3Conference Paper

Has antihypertensive treatment prevented vascular disease or vascular events?ZANCHETTI, A.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S1-S5, issn 0160-2446, SUP3Conference Paper

Role of calcium and endothelium in hypertension, cardiovascular disease, and subsequent vascular eventsVANHOUTTE, P. M.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S6-S10, issn 0160-2446, SUP3Conference Paper

Clinical equivalence of once-daily administration of a modified-release formulation of isradipine and twice-daily administration of the standard formulationHOLMES, D; MOULLET, C.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S61-S65, issn 0160-2446, SUP3Conference Paper

Postexercise reflex control of forearm vascular resistance during calcium antagonism with slow-release oral isradipineCLEROUX, J; N'GUESSAN KOUAME; YARDLEY, C et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S66-S69, issn 0160-2446, SUP3Conference Paper

Tolerability of isradipine in the treatment of mild-to-moderate hypertension in general practice: a large-scale surveillance studyHERMANS, L; BOGAERT, M; DEGAUTE, J. P et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S38-S45, issn 0160-2446, SUP3Conference Paper

Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence?WINTHER, K; GLEERUP, G; HEDNER, T et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S21-S24, issn 0160-2446, SUP3Conference Paper

Long-term antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal functionWITTENBERG, C; ROSENFELD, J. B.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S93-S95, issn 0160-2446, SUP3Conference Paper

Effects of calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertensionYU-AN DING; CHIH-LU HAN; TZ-CHONG CHOU et al.Journal of cardiovascular pharmacology. 1992, Vol 19, pp S32-S37, issn 0160-2446, SUP3Conference Paper